Press Releases

Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H

FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue clinical development of Auxora across indications LA JOLLA, Calif., June 24, 2026 /PRNewswire/ --

FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected

Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ D esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026 JCI Insight publication of preclinical

Safety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora ™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage